-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

565 A Phase 1b Study Evaluating the Safety and Efficacy of Venetoclax As Monotherapy or in Combination with Azacitidine for the Treatment of Relapsed/Refractory Myelodysplastic SyndromeClinically Relevant Abstract

Program: Oral and Poster Abstracts
Type: Oral
Session: 637. Myelodysplastic Syndromes—Clinical Studies: Combination Therapies
Hematology Disease Topics & Pathways:
Diseases, Therapies, Elderly, MDS, Study Population, Myeloid Malignancies
Monday, December 9, 2019: 7:00 AM
W311EFGH, Level 3 (Orange County Convention Center)

Amer M. Zeidan, MBBS, MHS1, Daniel A Pollyea, MD2, Jacqueline S Garcia, MD3, Andrew Brunner, MD4*, Fernando Roncolato, BMed, FRACP, FRCPA5*, Uma Borate, MD6, Olatoyosi Odenike, MD7, Ashish R. Bajel, FRACP8, Anne Marie Watson, FRACP, FRCPA, MBBS9, Katharina Götze10, Florian Nolte, MD11*, Peter T. Tan, MBBS12*, Wan-Jen Hong, MD13, Martin Dunbar, DRPH, MS14*, Ying Zhou, PhD14*, Lori Gressick, BS14*, William Ainsworth, PhD14, Jason Harb, PhD14*, Ahmed Hamed Salem, PhD, FCP15, John Hayslip16*, Ronan Swords, MD, PhD14 and Guillermo Garcia-Manero, MD17

1Department of Internal Medicine, Yale School of Medicine and Yale Cancer Center, Yale University, New Haven, CT
2Department of Hematology, University of Colorado, Denver, CO
3Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA
4Hematology/Oncology, Massachusetts General Hospital, Boston, MA
5University of New South Wales, Sydney, NSW, Australia
6Knight Cancer Institute, Division of Hematology & Medical Oncology, Oregon Health & Science University, Portland, OR
7Comprehensive Cancer Center, University of Chicago Medicine, Chicago, IL
8Royal Melbourne Hospital, Parkville, AUS
9Liverpool Hospital, Liverpool, AUS
10MLL Munich Leukemia Laboratory, Munich, Germany
11Department of Hematology and Oncology, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany
12Royal Perth Hospital, Perth, Australia
13Genentech, Inc., Mountain View, CA
14AbbVie Inc, North Chicago, IL
15AbbVie, North Chicago, IL
16AbbVie Inc., North Chicago, IL
17University of Texas MD Anderson Cancer Center, Department of Leukemia, Houston, TX

Introduction

Over-expression of the anti-apoptotic protein BCL-2 in MDS has been implicated in progression and drug resistance in MDS. Venetoclax (Ven), a selective, potent, orally bioavailable BCL-2 inhibitor, was recently approved in combination with HMAs or low dose cytarabine for the frontline management of older unfit pts with AML. In this study, we sought to evaluate the safety and efficacy of Ven in pts with R/R MDS.

Methods

This is an ongoing phase 1b, open-label, multicenter study in R/R MDS (NCT02966782). Key eligibility criteria include age ≥18 years, failure of HMA after receiving at least 4 cycles of Aza or 4 cycles of decitabine within the previous 5 years, marrow blasts <20%, and ECOG Performance status of ≤2. Cohort 1 (C1) pts received Ven monotherapy, either 400 mg (Arm A) or 800 mg (Arm B) per cycle (28 days) and Cohort 2 (C2) pts received Aza combined with escalating doses of Ven: 100, 200 and 400 mg daily for 14 of 28-day cycles. Aza was administered at the standard dose (75 mg/m2/day) for the first 7 days of each cycle.

The primary objectives were to evaluate the safety profiles and the recommended Phase 2 dose (RP2D) of Ven monotherapy and Ven+Aza. Key secondary objectives included a preliminary assessment of overall response rate (ORR, defined as complete remission [CR]+marrow complete remission [mCR]+partial response [PR]) , time to first response (TTR), progression-free survival (PFS), and overall survival (OS). We used the modified International Working Group 2006 criteria for response assessment (Cheson et. al., Blood, 2006).

Results

As of April 9, 2019, 46 pts [87% male, median age 76 years (range 44-91)] were enrolled. C1 (Ven monotherapy) included 22 pts, C2 (combination therapy) included 24 pts. At baseline, 37 (80%) pts received at least one prior therapy, 2 (15%) pts received 2, and 1 (2%) patient received >3 therapies prior to enrollment in the study. Baseline bone marrow blasts were: ≤5% was observed in 16 (35%) pts, >5% and ≤10% in 23 (50%), and >10% in 7 (15%) pts respectively. Cytogenetics risk was evaluated in 27/46 pts and were as follows: Good 12 (44%), Intermediate 9 (33%), and Poor 6 (22%).

Overall, 9 pts discontinued study therapy (8 deaths, 1 withdrew consent). The most frequent treatment-emergent adverse events (TEAEs) included neutropenia, thrombocytopenia, nausea, and diarrhea (Table ). Infectious TEAEs included febrile neutropenia and pneumonia. Predominant Grade 3 and 4 TEAEs were hematological and included neutropenia (41%), thrombocytopenia (30%), leukopenia (24%), and anemia (15%). Serious TEAEs occurring in ≥2 pts were febrile neutropenia (n=8), pneumonia (n=6), thrombocytopenia (n=2), and epistaxis (n=2). Death on study occurred in 8 (17%) pts, of whom 6 died of progressive disease. Other causes of death were septic shock (n=1) and pneumonia (n=1).

Forty of 46 pts were response evaluable. Median follow-up time was 4.7 mos (range: 3.7-6.3 mos). In C1, ORR was 7% (1/16). Stable disease was observed in 75% (12/16) pts. Median TTR was 1.6 mos (range: 1.6-1.6 mos). Median PFS was 3.4 mos (95% CI: 1.9-5.2 mos) and 6-mos estimate for OS was 57% (95% CI: 22%, 81%).

In C2, ORR was 50% (12/24 pts). Of those, 13% (3/24) had CR and 38% (9/24) had mCR. Stable disease was observed in 31% (10/24) pts. Median PFS, and OS were not reached. The 6-mos estimate for PFS was 76% (95% CI: 50%, 89%) and estimated OS at 9-mos was 83% (95% CI: 55%, 95%). Finally, 4 pts came off study to receive allogeneic stem cell transplantation.

Conclusion

Ven monotherapy and combination Ven+Aza were well tolerated in pts with R/R MDS and most AEs were manageable. Although the study is still ongoing, the 6-mos OS estimate of 57% in monotherapy pts compares favorably to historical controls. In addition, the ORR observed with combination therapy, and the observed 9-mos OS rate of 83% also compare favorably with historical data. Updated data on safety and efficacy, including data on RP2D, will be presented at the meeting.

Disclosures: Zeidan: Acceleron Pharma: Consultancy, Honoraria, Research Funding; Celgene Corporation: Consultancy, Honoraria, Research Funding; Abbvie: Consultancy, Honoraria, Research Funding; Otsuka: Consultancy, Honoraria, Research Funding; Pfizer: Consultancy, Honoraria, Research Funding; Medimmune/AstraZeneca: Research Funding; Boehringer-Ingelheim: Consultancy, Honoraria, Research Funding; Trovagene: Consultancy, Honoraria, Research Funding; Incyte: Consultancy, Honoraria, Research Funding; Takeda: Consultancy, Honoraria, Research Funding; ADC Therapeutics: Research Funding; Jazz: Honoraria; Ariad: Honoraria; Agios: Honoraria; Novartis: Honoraria; Astellas: Honoraria; Daiichi Sankyo: Honoraria; Cardinal Health: Honoraria; Seattle Genetics: Honoraria; BeyondSpring: Honoraria. Pollyea: Celyad: Consultancy, Membership on an entity's Board of Directors or advisory committees; Astellas: Consultancy, Membership on an entity's Board of Directors or advisory committees; Diachii Sankyo: Consultancy, Membership on an entity's Board of Directors or advisory committees; Pfizer: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; Janssen: Consultancy, Membership on an entity's Board of Directors or advisory committees; Abbvie: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; Takeda: Consultancy, Membership on an entity's Board of Directors or advisory committees; Agios: Consultancy, Membership on an entity's Board of Directors or advisory committees; Celgene: Consultancy, Membership on an entity's Board of Directors or advisory committees; Forty-Seven: Consultancy, Membership on an entity's Board of Directors or advisory committees; Gilead: Consultancy, Membership on an entity's Board of Directors or advisory committees. Garcia: Eli Lilly: Research Funding; Pfizer: Research Funding; Genentech: Research Funding; Abbvie: Membership on an entity's Board of Directors or advisory committees, Research Funding. Brunner: Novartis: Research Funding; Celgene: Membership on an entity's Board of Directors or advisory committees, Research Funding; Astra Zeneca: Research Funding; Forty Seven Inc: Membership on an entity's Board of Directors or advisory committees; Jazz Pharma: Membership on an entity's Board of Directors or advisory committees. Roncolato: St. George Hospital: Employment. Borate: Novartis: Consultancy; Takeda: Consultancy; Daiichi Sankyo: Consultancy; AbbVie: Consultancy; Incyte: Research Funding; Pfizer: Consultancy; Agios: Consultancy. Odenike: Astra Zeneca: Research Funding; Astex Pharmaceuticals: Research Funding; Agios: Research Funding; Celgene: Membership on an entity's Board of Directors or advisory committees, Research Funding; CTI/Baxalta: Research Funding; NS Pharma: Research Funding; Gilead Sciences: Research Funding; Incyte: Research Funding; AbbVie: Consultancy, Membership on an entity's Board of Directors or advisory committees; Janssen Oncology: Research Funding; Oncotherapy: Research Funding. Bajel: Amgen: Honoraria, Speakers Bureau; Novartis: Honoraria; AbbVie: Honoraria; Pfizer: Honoraria. Watson: Amgen: Other: Travel grant; Roche: Other: Travel grant. Götze: AbbVie: Membership on an entity's Board of Directors or advisory committees. Nolte: Novartis: Honoraria, Research Funding; Celgene: Honoraria, Research Funding. Tan: AbbVie Inc: Other: Investigator in AbbVie funded trial. Hong: Roche: Equity Ownership; Genentech Inc.: Employment, Equity Ownership. Dunbar: AbbVie Inc: Employment, Other: Stock/stock options. Zhou: AbbVie Inc: Employment, Other: Stock/stock options. Gressick: AbbVie Inc: Employment, Other: Stock/stock options. Ainsworth: AbbVie Inc: Employment, Other: Stock/stock options. Harb: AbbVie Inc: Employment, Other: Stock/stock options. Salem: AbbVie: Employment, Other: Stock/stock options. Hayslip: AbbVie Inc: Employment, Other: Stock/stock options. Swords: AbbVie Inc: Employment, Other: Stock/stock options. Garcia-Manero: Amphivena: Consultancy, Research Funding; Helsinn: Research Funding; Novartis: Research Funding; AbbVie: Research Funding; Celgene: Consultancy, Research Funding; Astex: Consultancy, Research Funding; Onconova: Research Funding; H3 Biomedicine: Research Funding; Merck: Research Funding.

OffLabel Disclosure: Venetoclax is a BCL-2 inhibitor that is FDA-approved in some indications. This presentation will focus on venetoclax for treatment in myelodysplastic syndromes, which is not an approved indication.

Previous Abstract | Next Abstract >>
*signifies non-member of ASH